6 天之前 · Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases.

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in discovering and developing treatment for serious chronic disease, like diabetes and obesity.

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in serious chronic disease treatment.

Our history spans a century and it all began with two small Danish companies, Nordisk Insulinlaboratorium and Novo Terapeutisk Laboratorium. After hearing of the discovery of insulin in 1921, Danish Nobel laureate August Krogh and …

Overview of Novo Nordisk pharmaceutical products within diabetes, obesity, haemophilia, human growth hormone and hormone replacement therapy.

2025年1月8日 · Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence

At Novo Nordisk, you will have the opportunity to build a life-changing career in a global business environment. Join us and make a difference.

In some cases, healthcare professionals and patients can visit local Novo Nordisk websites to find out more about our medicines. Please note that in some countries we are not allowed to provide very much, or sometimes any, information on our prescription medicines so you should seek alternative trustworthy sources.

6 Investor presentation First nine months of 2024 Novo Nordisk has tripled its glob increased its GLP-1 volume mark Global number of patients on GLP-1s acr

2024年10月21日 · Novo Nordisk A/S: Oral semaglutide demonstrates a 14% reduction in risk of major adverse cardiovascular events in adults with type 2 diabetes in the SOUL trial. Bagsværd, Denmark, 21 October 2024 — Novo Nordisk today announced the headline results from the SOUL cardiovascular outcomes trial. The double-blinded, randomised trial compared oral ...